BioCryst Pharmaceuticals (BCRX) said Monday that the Health Services Executive in Ireland has recommended Orladeyo for the routine prevention of recurrent attacks of hereditary angioedema in patients who are at least 12 years old.
The decision follows European Commission marketing authorization of the drug, also called berotralstat, in April 2021.
The orally ingested, once-daily drug is designed to prevent hereditary angioedema attacks by decreasing the activity of plasma kallikrein, the company said.
Price: 8.50, Change: +0.07, Percent Change: +0.83
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。